2/3
Katherine Unger Baillie
Senior Science News Officer
kbaillie@upenn.edu
The rates of advanced care planning conversations quadrupled, while potentially harmful therapy at end of life decreased by 25% in large randomized study.
The results of a study led by Penn Medicine’s Carl June greenlights preclinical trials for the application of CAR T therapy in gel form to surgical wounds following partial tumor removal to eliminate residual tumor cells.
The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression.
The injectable diagnostic, Cytalux, binds to cancerous tissue and glows, making it easier for surgeons to remove tumors completely while sparing healthy tissue.
Recent research shows promise in a novel CAR T therapy after cancer relapse, and a novel treatment for multiple myeloma.
A new study from the School of Nursing examines the association between patients’ perceived benefits and burdens of research participation and withdrawal.
A small molecule inhibitor that attacks the difficult cancer-causing gene mutation KRAS successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer.
Recent CDC data show that roughly four of every 10 cases of HPV-induced cancer now occur in men. Penn Medicine research has found that differences in levels of a particular HPV protein may inform treatment.
Penn Medicine researchers laud the early results for CAR T therapy in lupus patients, which point to broader horizons for the use of personalized cellular therapies.
Home care has long been a part of health care, but it was the COVID-19 pandemic that led Penn Medicine to rethink who needed to be in the hospital.
Katherine Unger Baillie
Senior Science News Officer
kbaillie@upenn.edu
A profile examines Penn Medicine’s commitment to the advancement of proton therapy, a new radiation cancer treatment, with remarks from James Metz and Justin E. Bekelman of the Perelman School of Medicine.
FULL STORY →
The Perelman School of Medicine’s Justin E. Bekelman is leading a $12 million study to compare the effects of proton therapy and standard radiation treatment on breast cancer.
FULL STORY →
Carl June and Avery Posey of the Perelman School of Medicine discuss the progression and expansion of CAR-T cell therapies.
FULL STORY →
Bruce Levine of the Perelman School of Medicine says that the latest results of Crispr gene editing in a cancer patient have showcased the best possible clinical outcome thus far.
FULL STORY →
Carl June of the Perelman School of Medicine says that off-the-shelf CAR-T cell therapies using CRISPR would be a game-changer.
FULL STORY →
A study by Nicola Mason of the School of Veterinary Medicine and colleagues found that an experimental immunotherapy treatment using genetically modified listeria could extend the life expectancy of dogs with cancer.
FULL STORY →